Cullinan Therapeutics showcases
Cullinan Therapeutics showcases preclinical data for autoimmune drug CLN-978
Cullinan Therapeutics will present significant preclinical data for their CD19-directed bispecific T cell engager, CLN-978. This development is part of their ongoing research efforts in tackling autoimmune diseases.
Set to be unveiled at ACR25 (American College of Rheumatology (ACR) Convergence 2025 meeting), the data supports the drug's clinical advancement in treating conditions such as lupus, rheumatoid arthritis, and Sjögren's disease. The presentation will delve into the potential applications of CLN-978, marking a step forward in autoimmune disease management.
About CLN-978
CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-978 potently triggers redirected lysis of CD19-expressing target cells in vitro and in vivo. CLN-978 is engineered to achieve very high affinity binding to CD19 to efficiently target B cells expressing very low CD19 levels. A human serum albumin (HSA)-binding domain increases the serum half-life of CLN-978 and, with subcutaneous delivery, permits more patient-friendly dosing and potentially reduced toxicity. CLN-978 contains two single-chain variable fragments, one binding with very high affinity to the CD19 target and the other binding to CD3 on T cells, and a single-domain antibody binding to HSA. CLN-978 was developed by an internal Cullinan team and is a wholly owned asset. CLN-978 has the potential to offer a convenient, off-the-shelf therapeutic option for patients with
autoimmune diseases such as SLE and rheumatoid arthritis.
About Cullinan Therapeutics
Cullinan Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer. The company uses a rigorous, strategic approach to build a diverse pipeline of potential first- or best-in-class molecules, with a core expertise in T cell engagers. Cullinan Therapeutics is headquartered in Cambridge, Massachusetts. The company's pipeline includes various modalities, such as T cell engagers (CLN-978, CLN-049), antibodies (CLN-619), small molecules (Zipalertinib), and fusion proteins (CLN-617).
